Sensei Biotherapeutics (STU:407) Debt-to-Asset : 0.09 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Debt-to-Asset?

Sensei Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €2.21 Mil. Sensei Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €1.46 Mil. Sensei Biotherapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was €43.32 Mil. Sensei Biotherapeutics's debt to asset for the quarter that ended in Dec. 2024 was 0.08.

Sensei Biotherapeutics Debt-to-Asset Historical Data

The historical data trend for Sensei Biotherapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Debt-to-Asset Chart

Sensei Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.02

0.07

0.08

0.09

Sensei Biotherapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.08	0.09	0.08	0.08	0.09

Competitive Comparison of Sensei Biotherapeutics's Debt-to-Asset

For the Biotechnology subindustry, Sensei Biotherapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sensei Biotherapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sensei Biotherapeutics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Sensei Biotherapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sensei Biotherapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.214	+	1.458)	/	43.32
	=	0.08

Sensei Biotherapeutics's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.214	+	1.458)	/	43.32
	=	0.08

Sensei Biotherapeutics (STU:407) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sensei Biotherapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sensei Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (STU:407) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SNSE:USA 407:Germany

Address

1405 Research Boulevard, Suite 125, Rockville, MD, USA, 20850

Website

https://www.senseibio.com

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).

Sensei Biotherapeutics Headlines

No Headlines